Defence Therapeutics Inc.
DTC
CNSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -113.83% | 39.04% | -26.23% | -15.36% | -29.24% |
| Total Depreciation and Amortization | -43.22% | -15.11% | 13.01% | -3.15% | -2.31% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.09% | -22.44% | -27.89% | 28.63% | 44.84% |
| Change in Net Operating Assets | 60.20% | -405.12% | 105.36% | -840.96% | -128.60% |
| Cash from Operations | -91.93% | 12.08% | 57.21% | -191.25% | -844.93% |
| Capital Expenditure | 128.10% | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -100.00% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 128.10% | -41.67% | -- | -100.00% | -- |
| Total Debt Issued | -100.00% | -- | -- | -- | -100.00% |
| Total Debt Repaid | 100.00% | -357.58% | 85.33% | 82.63% | -365.83% |
| Issuance of Common Stock | -- | -- | -100.00% | 426.88% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 99.63% | -2,220.29% | 97.21% | -1,056.07% | -- |
| Cash from Financing | -98.53% | 18,004.05% | -100.27% | 492.80% | 5,032.98% |
| Foreign Exchange rate Adjustments | -222.50% | 344.44% | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -224.67% | 229.05% | -145.09% | 271,720.00% | -100.91% |